Verona Pharma plc Verona Pharma Plc: Results Of Agm
16 April 2020 - 9:12PM
UK Regulatory
TIDMVRP
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP)
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, announces that all resolutions proposed at the
Annual General Meeting held today were duly approved by shareholders by
way of a poll. The
https://www.globenewswire.com/Tracker?data=UZ7F2WI6AhjjP-g8XncEHkPGqQZKVHjl0OmoQDCw5GzvbJMAlkuH71ptZjp7I0QDsbreVWQlVhwd5ssfchksOWtf9cNKfR7rooTyyyDn-IyvAczeGRroBY4mJuCwKML9PbP8uVM7yXcqpYaikxYWyw==
results of the poll are available on the Investors section of the
Company's website, www.veronapharma.com.
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs. If
successfully developed and approved, Verona Pharma's product candidate,
ensifentrine, has the potential to be the first therapy for the
treatment of respiratory diseases that combines bronchodilator and
anti-inflammatory activities in one compound. Verona Pharma is currently
evaluating three formulations of ensifentrine for the treatment of COPD
in Phase 2 clinical trials: nebulized, dry powder inhaler, and
pressurized metered-dose inhaler. Ensifentrine also has potential
applications in cystic fibrosis, asthma and other respiratory diseases.
For more information, please visit www.veronapharma.com.
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
-------------------------------------------- -------------------------
Victoria Stewart, Director of Communications info@veronapharma.com
-------------------------------------------- -------------------------
N+1 Singer Tel: +44 (0)20 3283 4200
-------------------------------------------- -------------------------
(Nominated Adviser and UK Broker)
Aubrey Powell / George Tzimas / Iqra
Amin (Corporate Finance)
Tom Salvesen (Corporate Broking)
-------------------------------------------- -------------------------
Optimum Strategic Communications Tel: +44 (0)20 3950 9144
(European Media and Investor Enquiries) verona@optimumcomms.com
-------------------------------------------- -------------------------
Mary Clark / Eva Haas / Hollie Vile
-------------------------------------------- -------------------------
Argot Partners Tel: +1 212-600-1902
(US Investor Enquiries) verona@argotpartners.com
-------------------------------------------- -------------------------
Stephanie Marks / Kimberly Minarovich /
Michael Barron
-------------------------------------------- -------------------------
(END) Dow Jones Newswires
April 16, 2020 07:12 ET (11:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma Plc News Articles